119 related articles for article (PubMed ID: 24568476)
1. Cervical cancer screening and analysis of potential risk factors in 43,567 women in Zhongshan, China.
Wang Y; Yu YH; Shen K; Xiao L; Luan F; Mi XJ; Zhang XM; Fu LH; Chen A; Huang X
Asian Pac J Cancer Prev; 2014; 15(2):671-6. PubMed ID: 24568476
[TBL] [Abstract][Full Text] [Related]
2. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
De Strooper LMA; Berkhof J; Steenbergen RDM; Lissenberg-Witte BI; Snijders PJF; Meijer CJLM; Heideman DAM
Int J Cancer; 2018 Sep; 143(6):1541-1548. PubMed ID: 29663363
[TBL] [Abstract][Full Text] [Related]
3. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
4. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
5. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China.
Pan QJ; Hu SY; Zhang X; Ci PW; Zhang WH; Guo HQ; Cao J; Zhao FH; Lytwyn A; Qiao YL
Cancer Cytopathol; 2013 Sep; 121(9):473-82. PubMed ID: 23907807
[TBL] [Abstract][Full Text] [Related]
6. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
7. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
8. Tubal ligation frequency in Oklahoma women with cervical cancer.
Mathews CA; Stoner JA; Wentzensen N; Moxley KM; Tenney ME; Tuller ER; Myers T; Landrum LM; Lanneau G; Zuna RE; Gold MA; Wang SS; Walker JL
Gynecol Oncol; 2012 Nov; 127(2):278-82. PubMed ID: 22858904
[TBL] [Abstract][Full Text] [Related]
9. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
[TBL] [Abstract][Full Text] [Related]
10. Application of human papillomavirus in screening for cervical cancer and precancerous lesions.
Wang JL; Yang YZ; Dong WW; Sun J; Tao HT; Li RX; Hu Y
Asian Pac J Cancer Prev; 2013; 14(5):2979-82. PubMed ID: 23803065
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
13. Can Genomic Amplification of Human Telomerase Gene and C-MYC in Liquid-Based Cytological Specimens Be Used as a Method for Opportunistic Cervical Cancer Screening?
Gao K; Eurasian M; Zhang J; Wei Y; Zheng Q; Ye H; Li L
Gynecol Obstet Invest; 2015; 80(3):153-63. PubMed ID: 25832290
[TBL] [Abstract][Full Text] [Related]
14. How many cervical cancer cases can potentially be prevented using a more sensitive screening test at young age?
de Kok IM; van Rosmalen J; Rozemeijer K; Penning C; van Ballegooijen M
Int J Cancer; 2014 Jan; 134(2):460-6. PubMed ID: 23824905
[TBL] [Abstract][Full Text] [Related]
15. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
16. [Factors associated with abnormal cervical cytology in pregnant women].
Fan L; Zou LY; Wu YM; Zhang WY
Zhonghua Fu Chan Ke Za Zhi; 2010 Feb; 45(2):109-13. PubMed ID: 20420780
[TBL] [Abstract][Full Text] [Related]
17. PAX1 methylation as a potential biomarker for cervical cancer screening.
Kan YY; Liou YL; Wang HJ; Chen CY; Sung LC; Chang CF; Liao CI
Int J Gynecol Cancer; 2014 Jun; 24(5):928-34. PubMed ID: 24844223
[TBL] [Abstract][Full Text] [Related]
18. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.
Agorastos T; Chatzistamatiou K; Katsamagkas T; Koliopoulos G; Daponte A; Constantinidis T; Constantinidis TC;
PLoS One; 2015; 10(3):e0119755. PubMed ID: 25793281
[TBL] [Abstract][Full Text] [Related]
19. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
[No Abstract] [Full Text] [Related]
20. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]